[{"orgOrder":0,"company":"Merck Millipore","sponsor":"Biovaxys","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"BVX-0320","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck Millipore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Merck Millipore \/ Millipore-Sigma","highestDevelopmentStatusID":"4","companyTruncated":"Merck Millipore \/ Millipore-Sigma"}]

Find Clinical Drug Pipeline Developments & Deals by Merck Millipore

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : BVX-1021 using a new batch of recombinant SARS-1 protein from the supplier that screened out the extraneous protein aggregate, has been synthesized using the purified SARS1 protein, OSU is now able to complete the neutralizing antibody studies.

                          Brand Name : BVX-1021

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 06, 2022

                          Lead Product(s) : BVX-1021,BVX-0320

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Biovaxys

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank